Anti-tumor activity and tolerability of hu14.18-IL2 with GMCSF and isotretinoin in recurrent or refractory neuroblastoma: a Children’s Oncology Group phase II study

PURPOSE: Combining anti-GD2 (disialoganglioside) monoclonal antibody with GM-CSF, IL2 and isotretinoin is now FDA-approved for high-risk neuroblastoma (NB) minimal residual disease (MRD) therapy. The humanized anti-GD2 antibody conjugated to IL2 (hu14.18-IL2) has clinical activity in NB and is more...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Cancer Res
Hlavní autoři: Shusterman, Suzanne, Naranjo, Arlene, Van Ryn, Collin, Hank, Jaquelyn A., Parisi, Marguerite T., Shulkin, Barry L., Servaes, Sabah, London, Wendy B., Shimada, Hiroyuki, Gan, Jacek, Gillies, Steven D., Maris, John M., Park, Julie R., Sondel, Paul M.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2019
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6945765/
https://ncbi.nlm.nih.gov/pubmed/31358541
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-0798
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky